Trial Profile

A Randomised Open-label Phase II Trial of Consolidation with Nivolumab and Ipilimumab in Limited-stage SCLC After Chemo-radiotherapy

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 11 Nov 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ipilimumab (Primary) ; Nivolumab (Primary) ; Carboplatin; Cisplatin; Etoposide
Indications Carcinoma; Small cell lung cancer
Focus Therapeutic Use
Acronyms STIMULI

Most Recent Events

08 Nov 2024 Status changed from active, no longer recruiting to completed.
31 Mar 2022 This trial has been completed in France, according to European Clinical Trials Database record.
28 Oct 2021 Planned End Date changed from 1 Jun 2022 to 1 Feb 2022.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com